With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex as the first-line treatment for ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...

A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease ...

Relay Therapeutics has demonstrated resilience in the face of competition at the European Society for Medical Oncology (ESMO) meeting, particularly with its PI3K inhibitors for advanced breast cancer.